Vol. 27. Núm. 6.
Páginas 263-270 (Junio 2020)

Actualizando la práctica asistencial
Valoración clínica de una neumonía: Criterios de sospecha de neumonía atípica, grave o tuberculosis

Teresa Biec AmigoaJaime Marín Cañadab
Doi : https://10.1016/j.fmc.2020.01.004
Opciones

Identifíquese

¿Aún no es suscriptor de la revista?

Comprar el acceso al artículo

Comprando el artículo el pdf del mismo podrá ser descargado

Teléfono para incidencias

De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h

Llamadas desde España 932 415 960
Llamadas desde fuera de España +34 932 415 960
Bibliografía
[1]
C.W. Lanks, A.I. Musani, D.W. Hsia.
Community-acquired pneumonia and hospital-acquired pneumonia.
Med Clin N Am., (2019), 103 pp. 487-501
[2]
L. Sharma, A. Losier, T. Tolbert, C.S. DelaCruz, C.R. Marion.
Atypical pneumonia. Updates on Legionella, Chlamydophila and Mycoplasma pneumoniae.
Clin Chest Med., (2017), 38 pp. 45-58
[3]
M.I. Irizar, M.A. Arrondo, M.J. Insausti, J. Mujica, P. Etxabarri, R. Ganzarain.
Epidemiología de la neumonía adquirida en la comunidad.
Aten Primaria., (2013), 45 pp. 503-513
[4]
J. Marín-Cañada, J.M. Molero-García, J. Redondo-Sánchez, R. Rodríguez-Barrientos.
Neumonía adquirida en la comunidad: tasa de incidencia en Madrid.
Estudio ATENAS. Aten Primaria., (2016), 48 pp. 615-616
[5]
H. Liu.
Community-Acquired bacterial pneumonia: Is there anything new?.
J Fam Pract., (2017), 66 pp. S10-S14
[6]
Instituto Nacional de Estadística. Defunciones según la causa de muerte. [Internet] [consultado el 5 de noviembre 2019]. Disponible en: https://www.ine.es/jaxiT3/Datos.htm?t=7947.
[7]
S. Jain, W.H. Self, R.G. Wunderin, S. Fakhran, R. Balk, A.M. Bramley, et al.
Community-Acquired Pneumonia Requiring Hospitalization among U.S.
Adults. N Engl J Med., (2015), 373 pp. 415-417
[8]
G.W. Waterer.
Diagnosing viral and atypical pathogens in the setting of community-acquired pneumonia.
Clin Chest Med., (2017), 38 pp. 21-28
[9]
J.P. Metlay, G.W. Waterer, A.C. Long, A. Anzueto, J. Brozek, K. Crothers, et al.
Diagnosis and Treatment of Adults with Community-acquired Pneumonia An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
Am J Respir Crit Care Med., (2019), 200 pp. e45-e67
[10]
R.F. Grossman, P.R. Hsueh, S.H. Gillespie, F. Blasi.
Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
Int J Infect Dis., (2014), 18 pp. 14-21
[11]
R. Hunton.
Updated concepts in the diagnosis and management of community-acquired pneumonia.
[12]
W.S. Lim, S.V. Baudoin, R.C. George, A.T. Hill, C. Jamieson, I. Le Jeune, et al.
British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009.
Thorax., (2009), 64 pp. iii1-iii55
[13]
G.H. Swingler, M. Zwarenstein.
Chest radiograph in acute respiratory infections.
Cochrane Database Syst Rev., (2009), 4 pp. CD001268
[14]
G.H. Groeneveld, J.W. van’t Wout, N.J. Aarts, C.J. van Rooden, T.J.M. Verheij, C.M. Cobbaert, et al.
Prediction model for pneumonia in primary care patients with an acute respiratory tract infection: role of symptoms, signs, and biomarkers.
BMC Infect Dis., (2019), 19 pp. 976
[15]
A. Schierenberg, M.C. Minaard, R.M. Hopstaken, A.C. Van de Pol, B.D.L. Broekhuizen, N.J. de Wit, et al.
External Validation of Prediction Models for Pneumonia in Primary Care Patients with Lower Respiratory Tract Infection: An Individual Patient Data Meta-Analysis.
PLoS ONE., (2016), 11 pp. e0149895
[16]
S.F. Van Vugt, B.D.L. Broekhuizen, C. Lammens, N.P.A. Zuithoff, P.A. de Jong, S. Coenen, et al.
Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study.
BMJ., (2013), 346 pp. f2450
[17]
P.S. Heckerling, T.G. Tape, R.S. Wigton, K.K. Hissong, J.B. Leikin, J.P. Ornato, et al.
Clinical prediction rule for pulmonary infiltrates.
Ann Intern Med., (1990), 113 pp. 664-670
[18]
NICE. National Institute for Health and Care Excellence. Pneumonia (including community acquired pneumonia). 2014. Disponible en: http://www.nice.org.uk/guidance/cg191 [consultado 22 de noviembre 2019].
[19]
NICE. Alere Afinion CRP for C-reactive protein testing in primary care. 2016 [consultado 22 de noviembre 2019]. Disponible en: https://www.nice.org.uk/advice/mib81/chapter/Summary.
[20]
NICE. QuikRead go for C-reactive protein testing in primary care. 2016 [consultado 22 de noviembre 2019]. Disponible en: https://www.nice.org.uk/advice/mib78/resources/quikread-go-for-creactive-protein-testing-in-primary-care-pdf-63499354178245.
[21]
M.C. Minnaard, J.A.H. de Groot, R.M. Hopstaken, A. Schierenberg, N.J. de Wit, J.B. Reitsma, et al.
The added value of C-reactive protein measurement in diagnosing pneumonia in primary care: a meta-analysis of individual patient data.
CMAJ., (2017), 189 pp. E56-E63
[22]
P. Schuetz, Y. Wirz, R. Sager, M. Christ-Crain, D. Stolz, M. Tamm, et al.
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.
Cochrane Database Syst Rev., (2017), 10 pp. CD007498
[23]
Y. Yu, A. Fei.
Atypical pathogen infection in community-acquired pneumonia.
BioScience Trends., (2016), 10 pp. 7-13
[24]
A. Capelastegui, P.P. España, A. Bilbao, J. Gamazo, F. Medel, J. Salgado, et al.
Poblational Study of Pneumonia (PSoP) Group Etiology of community-acquired pneumonia in a population-based study: Link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes.
BMC Infect Dis., (2012), 12 pp. 134-142
[25]
E.G.W. Huijskens, M. Koopmans, F.M.H. Palmen, A.J.M. van Erkel, P.G.H. Mulder, J.W.A. Rossen.
The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia.
JMM., (2014), 63 pp. 441-452
[26]
A. Chahin, S.M. Opal.
Severe pneumonia caused by Legionella pneumophila Differential diagnosis and therapeutic considerations.
Infect Dis Clin N Am., (2017), 31 pp. 111-121
[27]
R. Menéndez, A. Torres, J. Aspa, A. Capelastegui, C. Prate, F. Rodríguez de Castro.
Neumonía adquirida en la comunidad Nueva normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR).
Arch Bronconeumol., (2010), 46 pp. 543-558
[28]
G.D. Mills, M.R. Oehley, B. Arrol.
Effectiveness of lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
[29]
J.M. Molero, B. Benitez, A. Gallur, et al.
Infecciones del tracto respiratorio inferior Guía de uso de antimicrobianos en adultos con tratamiento ambulatorio v1. Madrid: Servicio Madrileño de Salud.
Consejería de Sanidad de la Comunidad de Madrid;, (2019), pp. 17
[30]
F. Sanz, N.M. Malanda, B. Montull, M.P. Sanjuán.
Nuevos retos en la neumonía comunitaria.
Arch Bronconeumol., (2010), 46 pp. 22-26
[31]
M.J. Fine, T.E. Auble, D.M. Yealy, B.H. Hanusa, L.A. Weissfeld, D.E. Singer, et al.
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med., (1997), 336 pp. 243-250
[32]
W.S. Lim, M.M. van der Eerden, R. Laing, W.G. Boersma, N. Karalus, G.I. Town, et al.
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.
Thorax., (2003), 58 pp. 377-382
[33]
O. Ochoa, A. Vila, R. Rodríguez, C. de Diego, E. Salsench, I. Hospital.
Utilidad de la escala de severidad modificada CRB75 en el manejo del paciente anciano con neumonía adquirida en la comunidad.
Aten Primaria., (2013), 45 pp. 208-215
[34]
A. Capelastegui, P.P. España, J.M. Quintana, I. Areitio, I. Gorordo, I. Egurrola, et al.
Validation of a predictive rule for the management of community-acquired pneumonia.
Eur Resp J., (2006), 27 pp. 151-157
[35]
D. Aujesky, T.E. Auble, D.M. Yealy, R.A. Stone, D.S. Obrosky, T.P. Meehan, et al.
Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia.
Am J Med., (2005), 118 pp. 384-392
[36]
M.S. Abers, D.M. Musher.
Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics.
QJM., (2014), 107 pp. 595-596
[37]
W.S. Lim, J.T. Macfarlane, T.C. Boswell, T.G. Harrison, D. Rose, M. Leinonen, et al.
Study of Community Acquired Pneumonia Aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.
Thorax., (2001), 56 pp. 296-301
[38]
M. Mc Nally, J. Curtain, K.K. O’Brien, B.D. Dimitrov, T. Fahey.
Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis.
Br J Gen Pract., (2010), 60 pp. e423-e433
[39]
A. Julián-Jiménez, E. García, J.I. García del Palacio.
Mortalidad y neumonía adquirida en la comunidad en el paciente anciano.
Arch Bronconeumol., (2016), 52 pp. 450-451
[40]
F. Saldías, A. O’Brien, A. Gederlini, G. Farías, A. Díaz.
Neumonía adquirida en la comunidad en el anciano inmunocompetente que requiere hospitalización Cuadro clínico, factores pronósticos y tratamiento.
Arch Bronconeumol., (2003), 39 pp. 333-340
[41]
J.H. Chen, S.S. Chang, J.J. Liu, R.C. Chan, J.Y. Wu, W.C. Wang, et al.
Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects.
Thorax., (2010), 65 pp. 971-977
[42]
O. Ochoa-Gondar, A. Vila-Corcoles, T. Rodriguez-Blanco, I. Hospital, E. Salsench, X. Ansa, et al.
Validation of the CORB75 (confusion, oxygen saturation, respiratory rate, blood pressure, and age 75 years) as a simpler pneumonia severity rule.
Infection., (2014), 42 pp. 371-378
[43]
S.M. Brown, N.C. Dean.
Defining and Predicting Severe Community-Acquired Pneumonia (SCAP).
Curr Opin Infect Dis., (2010), 23 pp. 158-164
[44]
J. González del Castillo, D.C. Wilson, C. Clemente-Callejo, F. Román, I. Bardés-Robles, I. Jiménez, et al.
Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
Critical Care., (2019), 23 pp. 335
[45]
R.F. Grossman, P.-R. Hsueh, S.H. Gillespie, F. Blasi.
Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
Int J Infect Dis., (2014), 18 pp. 14-21
[46]
C. Santiago Restrepo, R. Katre, A. Mumbower.
Imaging Manifestations of Thoracic Tuberculosis.
Radiol Clin North Am., (2016), 54 pp. 453-473
[47]
C.-K. Liam, Y.K. Pang, S. Poosparajah.
Pulmonary tuberculosis presenting as community-acquired pneumonia.
Respirology., (2006), 11 pp. 786-792
[48]
J. Domínguez, I. Latorrea, M. Miguel Santin.
Diagnóstico y abordaje terapéutico de la infección tuberculosa latente.
Enferm Infecc Microbiol Clin., (2018), 36 pp. 302-311
[49]
K.E. Dooley, J. Golub, F.S. Goes, et al.
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
Clin Infect Dis, (2002), 34 pp. 1607-1612